HIMS

28.15

2.96% -0.86

Handel nachbörslich: 28.18 0.03 +0.11%

Hims Hers Health Inc (HIMS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt HIMS? Forum Prognose

Schlusskurs vom Vortag:

$29.01

Offen:

$30.33

24-Stunden-Volumen:

44.67M

Relative Volume:

1.20

Marktkapitalisierung:

$6.42B

Einnahmen:

$2.35B

Nettoeinkommen (Verlust:

$128.37M

KGV:

53.92

EPS:

0.5221

Netto-Cashflow:

$57.42M

1W Leistung:

+4.30%

1M Leistung:

+25.33%

6M Leistung:

-41.95%

1J Leistung:

+5.39%

1-Tages-Spanne:

$27.03

$31.44

1-Wochen-Bereich:

$27.03

$31.86

52-Wochen-Spanne:

$13.74

$70.43

Hims Hers Health Inc Stock (HIMS) Company Profile

Firmenname

Hims Hers Health Inc

Sektor

Healthcare (1111)

Branche

Drug Manufacturers - Specialty & Generic (83)

Telefon

415-851-0195

Adresse

2269 CHESTNUT ST, SAN FRANCISCO

Mitarbeiter

2,442

Twitter

Nächster Verdiensttermin

2026-05-11

Neueste SEC-Einreichungen

HIMS's Discussions on Twitter

Compare HIMS vs TAK, ZTS, HLN, TEVA, UTHR

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
HIMS Hims Hers Health Inc	28.15	6.78B	2.35B	128.37M	57.42M	0.5221
TAK Takeda Pharmaceutical Co Adr	16.65	53.90B	29.85B	776.90M	4.35B	0.2408
ZTS Zoetis Inc	116.06	49.70B	9.47B	2.67B	2.28B	6.0218
HLN Haleon Plc Adr	9.53	42.40B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	31.21	36.43B	17.41B	1.43B	1.00B	1.2182
UTHR United Therapeutics Corp	572.85	25.13B	3.18B	1.33B	1.04B	27.90

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-03-10	Hochstufung	BofA Securities	Underperform → Neutral
2026-03-10	Hochstufung	Citigroup	Sell → Neutral
2026-03-09	Hochstufung	Needham	Hold → Buy
2026-02-24	Herabstufung	BTIG Research	Buy → Neutral
2026-01-12	Eingeleitet	Evercore ISI	In-line
2025-12-09	Eingeleitet	Barclays	Overweight
2025-10-21	Eingeleitet	KeyBanc Capital Markets	Sector Weight
2025-06-23	Herabstufung	Needham	Buy → Hold
2025-06-04	Bestätigt	Needham	Buy
2025-04-29	Herabstufung	TD Cowen	Buy → Hold
2025-02-18	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2025-01-10	Herabstufung	Citigroup	Neutral → Sell
2025-01-07	Eingeleitet	BTIG Research	Buy
2024-12-17	Eingeleitet	Morgan Stanley	Overweight
2024-11-14	Herabstufung	BofA Securities	Buy → Underperform
2024-08-22	Eingeleitet	Needham	Buy
2024-08-09	Herabstufung	Imperial Capital	Outperform → In-line
2024-05-22	Herabstufung	Citigroup	Buy → Neutral
2024-04-16	Herabstufung	Jefferies	Buy → Hold
2024-04-10	Eingeleitet	Canaccord Genuity	Buy
2024-02-28	Hochstufung	Imperial Capital	In-line → Outperform
2024-02-26	Eingeleitet	Leerink Partners	Market Perform
2023-12-07	Eingeleitet	Imperial Capital	In-line
2023-07-28	Eingeleitet	TD Cowen	Outperform
2023-04-11	Eingeleitet	Robert W. Baird	Neutral
2023-02-09	Hochstufung	Jefferies	Hold → Buy
2022-11-08	Hochstufung	BofA Securities	Neutral → Buy
2022-11-08	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2022-10-17	Herabstufung	Piper Sandler	Overweight → Neutral
2022-09-07	Eingeleitet	Truist	Hold
2022-07-15	Eingeleitet	SVB Leerink	Underperform
2022-04-14	Eingeleitet	Guggenheim	Buy
2022-04-01	Fortgesetzt	Credit Suisse	Outperform
2022-03-10	Eingeleitet	Deutsche Bank	Hold
2021-12-02	Eingeleitet	Jefferies	Hold
2021-11-11	Hochstufung	Piper Sandler	Neutral → Overweight
2021-07-06	Eingeleitet	BofA Securities	Neutral
2021-05-20	Hochstufung	Credit Suisse	Neutral → Outperform
2021-04-21	Eingeleitet	Truist	Hold
2021-03-09	Eingeleitet	Credit Suisse	Neutral
2021-03-02	Hochstufung	Citigroup	Neutral → Buy
2021-02-17	Eingeleitet	Citigroup	Neutral
2021-02-12	Eingeleitet	Piper Sandler	Neutral
2021-02-08	Eingeleitet	Tigress Financial	Buy

Alle ansehen

Hims Hers Health Inc Aktie (HIMS) Neueste Nachrichten

04:05 AM

Bronstein, Gewirtz & Grossman, LLC Encourages Hims & Hers Health - The National Law Review

04:05 AM

03:37 AM

Hims stock falls as GLP-1 shift raises questions on strategy - TradingView

03:37 AM

02:41 AM

Hims Stock Falls on Pivot From GLP-1 Compounding. Why the ‘Netflix’ Argument Is Failing. - Barron's

02:41 AM

02:17 AM

Hims stock price reacts strongly to crucial FDA review - thestreet.com

02:17 AM

02:12 AM

Eli Lilly (LLY) Expands Weight-Loss Offerings Through Hims & Hers Partnership - GuruFocus

02:12 AM

12:19 PM

Hims & Hers Positions Itself As Supply Anchor In Hormone Therapy Crunch - Benzinga

12:19 PM

11:38 AM

Hims & Hers (HIMS) Stock Jumps 7% After Expanding Eli Lilly GLP-1 Deal - CoinCentral

11:38 AM

11:22 AM

AI for investors - MLQ.ai

11:22 AM

11:01 AM

+1.37% for Hims & Hers Health stock as Novo Nordisk Wegovy collaboration adds branded therapies - Traders Union

11:01 AM

10:47 AM

BofA raises Hims and Hers stock price target on Lilly partnership - Investing.com Canada

10:47 AM

10:15 AM

LLY Sees Surge as Hims & Hers Expands Prescription Capabilities - GuruFocus

10:15 AM

10:06 AM

Hims & Hers jumps 7% after expanding partnership with Eli Lilly - Yahoo Finance

10:06 AM

09:45 AM

Why Hims & Hers Health, Inc. (HIMS) is a Top Growth Stock for the Long-Term - Yahoo Finance

09:45 AM

09:44 AM

Hims & Hers Adds Lilly GLP-1 Treatments To Lineup – CEO Compares It To Netflix’s Early Days - Stocktwits

09:44 AM

09:15 AM

Hims & Hers Health Legal Chief Sells Shares Worth Over $280000 - Koran Manado

09:15 AM

08:52 AM

Hims & Hers stock surges 7% on Eli Lilly partnership expansion - Investing.com Canada

08:52 AM

08:32 AM

Full Range of FDA-Approved GLP-1s Available on Hims & Hers - Hims & Hers Newsroom

08:32 AM

07:56 AM

Hims & Hers builds scalable data-driven personalized care platform - MSN

07:56 AM

06:08 AM

Hims & Hers (HIMS) Gets Good News from the FDA. Is It Already Priced in? - TipRanks

06:08 AM

04:20 AM

HIMS Stock Slides Premarket: Rival Telehealth Firm Ro Launches Aggressive Price Cuts In GLP-1 Subscription Fight - Stocktwits

04:20 AM

Apr 22, 2026

Insider Sell: Soleil Boughton Sells Shares of Hims & Hers Health Inc (HIMS) - GuruFocus

Apr 22, 2026

Hims & Hers chief legal officer Soleil Boughton sells $283,890 in stock - Investing.com Canada

Apr 22, 2026

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock - Investing.com

Apr 22, 2026

Hims & Hers CFO Oluyemi Okupe sells $588,615 in Hims stock By Investing.com - Investing.com Canada

Apr 22, 2026

Hims & Hers (HIMS) legal chief sells 9,463 shares in planned trade - Stock Titan

Apr 22, 2026

Hims & Hers (NYSE: HIMS) CFO option exercises and pre-planned share sale - Stock Titan

Apr 22, 2026

HIMS Expands Offerings for Menopause with Estrogen Patches - GuruFocus

Apr 22, 2026

Hims & Hers offers estrogen patches as US demand surges - USA Today

Apr 22, 2026

Hims & Hers says it has steady estrogen patch supply amid US shortages - Reuters

Apr 22, 2026

Hims & Hers doubles down on estrogen patches as demand surges - Seeking Alpha

Apr 22, 2026

HIMS Expands Into Menopause Care But Amazon’s GLP-1 Program Weighs On Stock - Stocktwits

Apr 22, 2026

Hims & Hers Health stock price forecast: $25.24 support in focus as HIMS slips 3.83% - Traders Union

Apr 22, 2026

Navigating the Estrogen Patch Shortage with Hers - Hims & Hers Newsroom

Apr 22, 2026

HIMS Stock Pares Losses After-Hours: Citi Flags ‘Big Caveat’ In Amazon’s GLP-1 Push That Limits Risk To Hims Model - Stocktwits

Apr 22, 2026

HIMS plunges 51.2% in 6 months: Should you still hold the stock or sell? - MSN

Apr 22, 2026

Apr 21, 2026

HIMS stock pares losses after-hours: Citi flags 'big caveat' in Amazon's GLP-1 push that limits risk to Hims model - MSN

Apr 21, 2026

Hims & Hers Health stock falls after Amazon launches GLP-1 program - Investing.com Canada

Apr 21, 2026

Is Hims & Hers Health Inc (HIMS) a Bargain After 4.0% Drop? GF V - GuruFocus

Apr 21, 2026